You are here

Article Text

Article menu
Download PDFPDF
Review
Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety
  1. K L Hyrich,
  2. A J Silman,
  3. K D Watson,
  4. D P M Symmons
  1. ARC Epidemiology Unit, University of Manchester, UK
  1. Correspondence to:
    Professor A J Silman
    ARC Epidemiology Unit, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK; alan.Silmanman.ac.uk

Abstract

Anti-TNFα therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.

  • ANA, antinuclear antibody
  • CHF, congestive heart failure
  • DMARD, disease modifying antirheumatic drug
  • dsDNA, double stranded DNA
  • FDA, Federal Drug Administration
  • MS, multiple sclerosis
  • RA, rheumatoid arthritis
  • SLE, systemic lupus erythematosus
  • TB, tuberculosis
  • TNFα, tumour necrosis factor α
  • anti-tumour necrosis factor α
  • rheumatoid arthritis
  • safety

https://doi.org/10.1136/ard.2004.024737

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes